Explainer: Why no vaccine can ever be 100% effective | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Monday
May 29, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
MONDAY, MAY 29, 2023
Explainer: Why no vaccine can ever be 100% effective

Coronavirus chronicle

TBS Report
01 December, 2020, 11:25 am
Last modified: 01 December, 2020, 11:27 am

Related News

  • G7 plans new vaccine effort for developing nations, Yomiuri reports
  • Malaria vaccine gets green light for use in Ghana
  • Cancer and heart disease vaccines expected to be ready by 2030
  • China OKs its first mRNA vaccine, from drugmaker CSPC
  • Vaccine makers prep bird flu shot for humans 'just in case'; rich nations lock in supplies

Explainer: Why no vaccine can ever be 100% effective

The three recently reported coronavirus vaccines with efficacy rates of up to 95 per cent are actually high relative to other vaccines; for example, flu jab is only 50 per cent effective on average.

TBS Report
01 December, 2020, 11:25 am
Last modified: 01 December, 2020, 11:27 am
Representational image. Photo: Collected
Representational image. Photo: Collected

The world eagerly welcomed the news of the three new coronavirus vaccines, in particular their efficacy.

Preliminary results of clinical trials indicate their efficacy ranging from 62 percent to 95 percent.

None of them recorded 100% and that could sound disconcerting. But the reality is no vaccine does that. Indeed the latest coronavirus jabs may provide better safety than many other vaccines, experts say.

"Seventy or 90 per cent effectiveness is remarkably high," Dr Andrew Preston, a reader in microbial pathogenesis at the University of Bath, told The Daily Mail. "The vaccine may not stop the person catching the infection, but it would stop them getting symptoms of the disease if they caught it."

But why can't a vaccine offer full protection, and does it matter?

Vaccines function by developing a 'memory' of the disease once the immune system comes into contact with it again—it identifies the disease and causes a 'bigger and longer-lasting response' which means that it has little chance of taking hold and causing symptoms, explains Will Irving, professor of virology at the University of Nottingham.

Vaccines work by creating a 'memory' of the disease should the immune system come into contact with it again — it recognises the disease and triggers a, which means it doesn't have a chance to take hold and cause symptoms, explains Will Irving, a professor of virology at the University of Nottingham.

"When developing any vaccine, clinical trials are carried out to find out whether it is effective and if it is, how good it is," he explains.

"To do this you have a group of people that's vaccinated and another that isn't, the placebo group. You then count the number of cases of the disease in each group over a period. If you have 25 cases of disease in the vaccinated group and 50 cases in the placebo, the vaccine is 50 per cent effective — i.e. it has prevented half the people in the vaccinated group from getting the disease."

Although the goal is a 100% effective vaccine, it is difficult to attain because human make-up is so different from one another.

The three recently reported coronavirus vaccines with efficacy rates of up to 95 per cent are actually high relative to other vaccines; for example, flu jab is only 50 per cent effective on average.

Compared to two doses of measles, mumps and rubella (MMR) jab, 99 per cent of people will be safe from measles and rubella and 88 per cent from mumps; while whooping cough vaccine is initially 80 per cent successful, safety declines to 60 per cent after four years, the Canadian Medical Association Journal reported in 2016—which is why children have booster jabs.

"There is too much variation in the population's immune systems for any vaccine to be 100 per cent effective," says Dr Preston. "For example, as we age, our immune system responds less well, which means vaccinating older people in general is a problem.

"That's why the flu and pneumonia vaccines, which are largely aimed at older people, contain adjuvants — compounds that boost the immune response to the vaccine, meaning we are more likely to produce antibodies and be protected."

Any condition that weakens the immune system, including obesity, may also affect our response to a vaccine.

"Obesity creates an inflammatory state in the body and it's thought the heightened inflammatory state may exhaust the immune system, making it less able to respond to vaccines," explains Dr Preston.

Vaccination is not about preventing symptoms in the individual—it may also stop the disease from circulating.

For example, if more than 90% of citizens are vaccinated with MMR jab, this decreases the amount of circulating disease and thus prevents those that are not vaccinated—so-called herd immunity. In the end, this will lead to the eradication of a disease, as with smallpox (the jab was 95 per cent effective).

How many people need a Covid-19 vaccine to establish herd immunity is unclear; it depends on how contagious the disease is—the 'R' or reproductive rate—and how successful the vaccine is.

"If measles vaccination rates drop below 90 per cent, for ex-ample, there are outbreaks of the disease because measles is fantastically infectious, with an R of around 15," says Professor Irving, explaining that SARS-coV-2 (the virus that causes Covid infections) has an R rate of up to 3.

It's also not clear whether the one in ten who are vaccinated against Covid-19 and yet to show symptoms would be more severely ill if they hadn't had the vaccine.

Another unknown is whether being vaccinated will stop people from being infectious, so called sterilising immunity.

"All vaccines are designed to stop the disease they are targeted against, but it is very difficult to generate immunity that actually stops infection," says Dr Preston.

"So no matter how many people are vaccinated, the virus will still circulate. This is the case with the whooping cough vaccine.

"It stops the Bordetella pertussis bacterium infecting the lungs, which causes this dangerous disease, but it doesn't stop people from becoming infected in their upper airways, and these people can still transmit the infection. Until we have more answers, science has to be transparent, says Dr Preston.

"No medicine is without risk and we need to be honest about that while at the same time fighting disinformation," he says.

Top News

Vaccine / effective / Coronavirus

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Govt's borrowing from treasury bills up by Tk65,000cr in FY23
    Govt's borrowing from treasury bills up by Tk65,000cr in FY23
  • Infographic: TBS
    Inside Airbus's mega plan to develop the aviation ecosystem in Bangladesh
  • President Joe Biden delivers the State of the Union address to a joint session of Congress at the Capitol, Tuesday, Feb. 7, 2023, in Washington. Jacquelyn Martin/Pool via REUTERS
    Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress

MOST VIEWED

  • Covid is no longer global health emergency: WHO
    Covid is no longer global health emergency: WHO
  • Federal police officers stand guard near the house of former Brazilian President Jair Bolsonaro, during a search operation at his home, in Brasilia, Brazil, 3 May, 2023. REUTERS/Adriano Machado
    Bolsonaro home raided, phone seized in Brazil vaccine records probe
  • World Health Organization logo is reflected in a drop on a syringe needle in this illustration photo taken March 16, 2021. REUTERS/Dado Ruvic/Illustration//File Photo
    Covid here to stay but moving out of emergency phase: WHO
  • India's active case count now stands at 3.90 per cent. ( HT file Photo)
    India reports 12,591 new Covid cases today, 20% more than yesterday
  • People queue up outside a quick test centre to take their coronavirus disease (Covid-19) antigen rapid tests, in Singapore September 21, 2021. Photo :Reuters
    Singapore witnesses new Covid wave: ‘Cases are mostly mild’
  • India's active case count now stands at 3.90 per cent. ( HT file Photo)
    India logs 5,676 new Covid cases, active infections cross 37,000-mark

Related News

  • G7 plans new vaccine effort for developing nations, Yomiuri reports
  • Malaria vaccine gets green light for use in Ghana
  • Cancer and heart disease vaccines expected to be ready by 2030
  • China OKs its first mRNA vaccine, from drugmaker CSPC
  • Vaccine makers prep bird flu shot for humans 'just in case'; rich nations lock in supplies

Features

Infographic: TBS

Inside Airbus's mega plan to develop the aviation ecosystem in Bangladesh

1h | Panorama
How women's purchasing power is altering market dynamics

How women's purchasing power is altering market dynamics

24m | Panorama
Unwinding poolside, she revels in self-care, her flawless complexion glowing under the gentle sun. Photo: Rony Rezaul. Model: Tangia Zaman Methila

Dive into Summer Style: Get Ready to Sizzle by the Pool

22h | Mode
Illustration: TBS

'Cybercriminals are creating new ways of hacking'

1d | Panorama

More Videos from TBS

Turks are voting in presidential run-off

Turks are voting in presidential run-off

17h | TBS World
Temperature will surpass 1.5 degree by 2027

Temperature will surpass 1.5 degree by 2027

1d | TBS World
Dubai’s gigantic moon shaped mega resort

Dubai’s gigantic moon shaped mega resort

1d | TBS World
In an interview given to TBS Lt. Col. Mohammad Tajul Islam Chowdhury

In an interview given to TBS Lt. Col. Mohammad Tajul Islam Chowdhury

3d | TBS Stories

Most Read

1
End of zero tax!
NBR

End of zero tax!

2
Photo: TBS
Energy

Wind power feeds national grid for first time Friday

3
Photo: TBS
Bangladesh

Private helicopter service launched in Ctg

4
Malaysian ship docks at Mongla port with 926 luxurious cars
Bangladesh

Malaysian ship docks at Mongla port with 926 luxurious cars

5
Nagad builds hope on Tk510cr bond, incurs Tk625cr loss
Economy

Nagad builds hope on Tk510cr bond, incurs Tk625cr loss

6
Cenbank prints Tk70,000cr new money in 11 months to support nat'l budget
Budget

Cenbank prints Tk70,000cr new money in 11 months to support nat'l budget

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]